The Majorcan biochemist Miquel F. Segura Ginard leads an ambitious European project that aims to open a new avenue in the treatment of childhood cancer. From the Vall d’Hebron Research Institute (VHIR), Segura coordinates PHOENIX, an initiative funded with 8.5 million euros by the European Union that will promote the first pediatric clinical trial with the experimental drug ibrilatazar.